Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetuzumab Govitecan in Metastatic Colorectal Cancer
NCT01605318Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2013
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
A Phase 2 trial of labetuzumab govitecan in colorectal cancer (CRC), sponsored by Gilead Sciences. Started Feb 2013; status: terminated.
02
Drugs
labetuzumab govitecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01605318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605318.